Prosecution Insights
Last updated: August 15, 2026
Application No. 18/253,521

Crystalline Forms of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, Methods of Preparation, and uses Thereof

Non-Final OA §112
Filed
May 18, 2023
Priority
Nov 20, 2020 — provisional 63/116,191 +2 more
Examiner
FETTEROLF, BRANDON J
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Taiho Pharmaceutical Co., Ltd.
OA Round
3 (Non-Final)
51%
Grant Probability
Moderate
3-4
OA Rounds
4m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants 51% of resolved cases
51%
Career Allowance Rate
110 granted / 214 resolved
-8.6% vs TC avg
Strong +17% interview lift
Without
With
+17.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
60 currently pending
Career history
265
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
28.3%
-11.7% vs TC avg
§102
20.8%
-19.2% vs TC avg
§112
29.0%
-11.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 214 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6/12/2026 has been entered. Claims 1-2, 6, 13, 17-24 and 26-34 are currently pending and under consideration. Information Disclosure Statement The information disclosure statements filed on 3/23/2026 and 6/12/2026 are acknowledged and have been considered except where lined through. Rejections Maintained: Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 19-20, 23-24, and 27-32 remain rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 19-20, 23-24, and 27-32, each of the claims are drawn to a crystal, wherein the crystal comprises 50% or 99% of the crystal of a different claim. A crystal comprising a certain percentage of a crystal of a different claim is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. For example, the specification and claims do not appear to teach which portion of the crystal of the previous claim is supposed to be “maintained” and which is to be excluded. In response to this rejection, Applicants contend, referring to claim 19 as an example, the phrase “A crystal of… comprising at least 50% of the crystal of claim 17” means that the crystal of claim 19 includes a portion of at least 50% of the crystal of claim 19 that satisfies the features recited in claim 17. By way of analogy, Applicants assert that this wording is analogous to a hypothetical claim 19 that recites a composition comprising at least 50% by weight of the compound of claim 17. These arguments have been carefully considered, but are not found persuasive. First, as noted above, the specification, as originally filed, does not appear to define what is encompassed by a crystal comprising a portion of a least 50% or 99% of another crystal. In particular, the specification and claims do not appear to teach which portion of the crystal of the previous claim is supposed to be “maintained” and which is to be excluded. Regarding Applicants analogy, the Examiner disagrees that a comprising 50% by weight of the compound of claim 17 is analogous to what is being claimed in the instant application. In the analogous example, the composition has to comprise the compound. This is not the case in the instant claims. Only 50% of the crystal is present and the specification and claims do not appear to teach which portion of the crystal of the previous claim is supposed to be “maintained” and which is to be excluded. New Rejections: Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 19-20, 23-24, and 27-32 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. THIS IS A NEW MATTER REJECTION. Claims 19-20, 23-24, and 27-32 are drawn to a crystal, wherein the crystal comprises 50% or 99% of the crystal of a different claim. In the response to the Non-Final rejection of 10/02/2025, Applicants asserted that support for the claims can be found at least in paragraph 0080 of the specification. However, a careful review of the specification, as originally filed, does not lend support for a crystal, wherein the crystal comprises 50% or 99% of the crystal of a different claim. The only support for %’s appears to be paragraph 0097 which states: PNG media_image1.png 78 632 media_image1.png Greyscale Accordingly, this does not appear to explicitly or implicitly provide support for a crystal comprising 50% or 99% of a crystal of a different claim. In particular, paragraph 0097 appears to be directed to the crystalline form. Note: While the Examiner did not previously apply this rejection, the rejection has been applied upon reconsideration of the 112 (b) above and Applicants not providing a definition supported in the specification. Conclusion Claims 1-2, 6, 13, 17-18, 21-22, 26 and 33-34 are free of the prior art. As noted in the prior office action, the closest prior art is Miyazaki et al. (US10,155,768B2, 2018-12-18, IDS) whom teaches the claimed compound (example 85) and also contemplates crystalline forms (column 87, lines 34-46). While the prior art contemplates crystalline forms, the prior art does not explicitly teach the synthesis of these crystalline forms. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRANDON J FETTEROLF whose telephone number is (571)272-2919. The examiner can normally be reached M-F 6AM-4PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey S Lundgren can be reached at 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRANDON J FETTEROLF/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

May 18, 2023
Application Filed
Oct 02, 2025
Non-Final Rejection mailed — §112
Feb 02, 2026
Response Filed
Mar 12, 2026
Final Rejection mailed — §112
Jun 12, 2026
Request for Continued Examination
Jun 16, 2026
Response after Non-Final Action
Jul 16, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12692247
PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1
2y 5m to grant Granted Jul 28, 2026
Patent 12679817
PROCESSES FOR THE PREPARATION OF THE ENANTIOMERS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE (MBDB)
2y 8m to grant Granted Jul 14, 2026
Patent 12679804
2-(3-ETHYNYLBENZYL)-SUBSTITUTED HETEROCYCLE DERIVATIVES AND RELATED USES
2y 9m to grant Granted Jul 14, 2026
Patent 12662454
HYDROXY-PYRIDINALDOXIME SCAFFOLDS
3y 3m to grant Granted Jun 23, 2026
Patent 12661349
PHARMACEUTICALLY ACCEPTABLE SALT OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST, AND CRYSTALLINE FORM THEREOF
2y 8m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
51%
Grant Probability
68%
With Interview (+17.1%)
3y 7m (~4m remaining)
Median Time to Grant
High
PTA Risk
Based on 214 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month